Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program
- PMID: 18551382
- DOI: 10.1007/s11096-008-9232-5
Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program
Abstract
Objectives: To measure the positive predictive value (PPV) of the cost of drug therapy (threshold = 2000 Swiss francs [CHF], US$1440, <euro>1360) as a screening criterion for identifying patients who may benefit from medication review (MR). To describe identified drug-related problems (DRPs) and expense problems (EPs), and to estimate potential savings if all recommendations were accepted.
Setting: Five voluntary Swiss community pharmacies.
Methods: Of 12,680 patients, 592 (4.7%) had drug therapy costs exceeding 2000 CHF over a six-month period from July 1 to December 31, 2002. This threshold limit was set to identify high-risk patients for DRPs and EPs. Three pharmacists consecutively conducted a medication review based on the pharmaceutical charts of 125 sampled patients who met the inclusion criterion.
Main outcome measure: The PPV of a threshold of 2000 CHF for identifying patients who might benefit from a MR: true positives were patients with at least one DRP, while false positives were patients with no DRP.
Results: The selection based on this criterion had a PPV of 86% for detecting patients with at least one DRP and 95% if EPs were also considered. There was a mean of 2.64 (SD = 2.20) DRPs per patient and a mean of 2.14 (SD = 1.39) EPs per patient. Of these patients, 90% were over 65 years old or were treated with at least five chronic medications, two common criteria for identifying patients at risk of DRPs. The main types of DRPs were drug-drug interactions, compliance problems and duplicate drugs. Mean daily drug cost per patient was CHF 14.87 (US$10.70, <euro>10.10). A potential savings of CHF 1.67 (US$1.20, <euro>1.14) per day (11%) was estimated if all recommendations to solve DRPs and EPs suggested herein were implemented.
Conclusion: Further studies should investigate whether the potential benefit of medication reviews in preventing DRPs and containing costs in this patient group can be confirmed in a real practice environment.
Similar articles
-
Relationship between drug-related problems and health outcomes: a cross-sectional study among cardiovascular patients.Pharm World Sci. 2010 Aug;32(4):512-9. doi: 10.1007/s11096-010-9401-1. Epub 2010 Jun 5. Pharm World Sci. 2010. PMID: 20526741
-
Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands.Int J Clin Pharm. 2016 Feb;38(1):46-53. doi: 10.1007/s11096-015-0199-8. Epub 2015 Nov 23. Int J Clin Pharm. 2016. PMID: 26597955 Free PMC article.
-
Practical evaluation of the drug-related problem management process in Swiss community pharmacies.Pharm World Sci. 2008 Dec;30(6):777-86. doi: 10.1007/s11096-008-9217-4. Epub 2008 Apr 6. Pharm World Sci. 2008. PMID: 18392732
-
Pharmaceutical care in community pharmacies: practice and research in Sweden.Ann Pharmacother. 2006 Jun;40(6):1162-9. doi: 10.1345/aph.1G680. Epub 2006 May 30. Ann Pharmacother. 2006. PMID: 16735653 Review.
-
Identification, classification, and documentation of drug related problems in community pharmacy practice in Europe: a scoping review.Int J Clin Pharm. 2025 Apr;47(2):247-269. doi: 10.1007/s11096-024-01834-7. Epub 2025 Jan 8. Int J Clin Pharm. 2025. PMID: 39775382 Free PMC article.
Cited by
-
Drug-related problems in diabetes and transplant patients: an observational study with home visits.Int J Clin Pharm. 2011 Oct;33(5):815-23. doi: 10.1007/s11096-011-9542-x. Epub 2011 Aug 3. Int J Clin Pharm. 2011. PMID: 21811831
-
Relationship between drug-related problems and health outcomes: a cross-sectional study among cardiovascular patients.Pharm World Sci. 2010 Aug;32(4):512-9. doi: 10.1007/s11096-010-9401-1. Epub 2010 Jun 5. Pharm World Sci. 2010. PMID: 20526741
-
Application of drug-related problem (DRP) classification systems: a review of the literature.Eur J Clin Pharmacol. 2014 Jul;70(7):799-815. doi: 10.1007/s00228-014-1686-x. Epub 2014 May 2. Eur J Clin Pharmacol. 2014. PMID: 24789053 Review.
-
Drug expenditure of high-cost patients and their characteristics in Finland.Eur J Health Econ. 2013 Jun;14(3):495-502. doi: 10.1007/s10198-012-0393-8. Epub 2012 May 12. Eur J Health Econ. 2013. PMID: 22581227
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous